Dare Bioscience Launches First Commercial Product, Reports Q2 Results and Positive Ovaprene Data
DARE sits 21% above its 52-week low of $1.13.
Summary
Dare Bioscience launched its first commercial product, Flora Sync LF5, and reported Q2 2026 results showing $0.2M revenue and a $3.0M net loss. Positive Ovaprene Phase 3 interim data and DARE-HPV Phase 2 initiation were also announced.
Key Events · Earnings and Guidance · DARE
-
First Commercial Product Launch
Flora Sync LF5 launched through the DARE Health Hub, marking the company's first directly commercialized product, with revenue beginning in July 2026.
-
Q2 2026 Financial Results
Revenue was $0.2 million, net loss was $3.0 million, and cash and cash equivalents were $12.6 million as of June 30, 2026, with a working capital deficit of $0.2 million.
-
Positive Ovaprene Phase 3 Interim Data
The independent Data Safety Monitoring Board recommended the pivotal Phase 3 study continue without modification after positive interim results.
-
DARE-HPV Phase 2 Study Initiated
A Phase 2 study for DARE-HPV, funded by an ARPA-H award, has been initiated and is expected to enroll approximately 100 women, with topline results expected in 2027.
Analysis · DARE · Life Sciences
Dare Bioscience reported Q2 2026 results alongside a commercial inflection: its first directly commercialized product, Flora Sync LF5, launched and began generating revenue in July. The company also disclosed positive interim Phase 3 Ovaprene data and initiation of the DARE-HPV Phase 2 study. Cash stands at $12.6 million with a working capital deficit of $0.2 million, and the company faces a Nasdaq delisting notice from July 2026. The launch and pipeline progress are meaningful for a micro-cap company transitioning from development to commercialization, but the financial position remains tight.
At the time of this filing, DARE was trading at $1.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.5M. The 52-week trading range was $1.13 to $3.78. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.